WEBULL
News
CNTA
24.85
0.00%
0.00
Wells Fargo Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)
TipRanks · 1d ago
Weekly Report: what happened at CNTA last week (1208-1212)?
Weekly Report · 4d ago
Centessa Pharmaceuticals (CNTA): Assessing Valuation After New CEO Appointment and Refined Orexin-Focused Strategy
Simply Wall St · 4d ago
These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025
TipRanks · 12/11 22:50
Centessa falls -8.4%
TipRanks · 12/11 15:05
Centessa Pharmaceuticals CEO Saurabh Saha To Step Down; Mario Accardi Named Replacement
NASDAQ · 12/11 13:47
Centessa Pharmaceuticals Appoints New CEO Amid Strategic Shift
TipRanks · 12/11 13:18
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Regeneron (REGN) and Elicio Therapeutics (ELTX)
TipRanks · 12/11 13:10
Strategic Leadership and Orexin Program Expansion Boost Centessa Pharmaceuticals’ Growth Potential
TipRanks · 12/11 13:05
Centessa CEO Saurabh Saha to step down, Mario Alberto Accardi to succeed
TipRanks · 12/11 12:10
Centessa Pharmaceuticals Price Target Raised to $62.00/Share From $40.00 by Oppenheimer
Dow Jones · 12/10 16:47
Centessa Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Dow Jones · 12/10 16:47
Oppenheimer Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $62
Benzinga · 12/10 16:36
Oppenheimer Reaffirms Their Buy Rating on Centessa Pharmaceuticals (CNTA)
TipRanks · 12/10 12:55
Centessa assumed with an Outperform at Oppenheimer
TipRanks · 12/10 12:45
ORX750 Trial Success and Equity Raise Might Change The Case For Investing In Centessa Pharmaceuticals (CNTA)
Simply Wall St · 12/09 07:08
Weekly Report: what happened at CNTA last week (1201-1205)?
Weekly Report · 12/08 10:27
13D Filings
Barron‘s · 12/05 23:35
Centessa Pharmaceuticals Price Target Raised to $42.00/Share From $33.00 by B. Riley Securities
Dow Jones · 12/01 15:16
Centessa Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Dow Jones · 12/01 15:16
More
Webull provides a variety of real-time CNTA stock news. You can receive the latest news about Centessa Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.